US Branded Generics Market Archives

Rising number of chronic illnesses, rise in ANDA applications and approvals, channel consolidation and significant price pressure, portfolio reduction by MNCs, patent expiry of important pharmaceuticals, and entry of Indian competitors are some of the main drivers driving the US branded generics market growth. However, greater costs relative to unbranded generics are one of the key factors influencing market growth. Branded generics are generic medications with a proprietary market name. It can be manufactured by either a generic pharmaceutical company or the original manufacturer and commercialized after the original drug’s patent expires. They are offered using a brand name rather than a chemical name. An abbreviated new drug application (ANDA) is filed with the regulatory authority to market branded generics, and it must be therapeutically equivalent to the original drug for which the patent has expired. To know more about the research report, fill out a quick inquiry for a sample report: https://meditechinsights.com/us-branded-generics-market/request-sample/ Advantages Offered By Branded Generics Fuels Their Adoption in the US Branded Generics Market See also Global Albumin Market Expects Steady Growth with a 6% CAGR by 2026 Due to the multiple advantages offered by branded generics, their adoption is expected to rise in the United States. Following are the advantages:- They are sold as alternatives to brand-name drugs and are relatively less expensive For combination drugs it is difficult to remember their generic names. Branded generics can be easily remembered. Attract several consumers who prefer branded drugs only. They provide quality assurance from well-established companies. “Branded generics comprise only a small percentage of total generic prescriptions in the U.S. but they are more profitable than unbranded generics..…”– Tier I Branded Generic Manufacturer, USA Foray of India Players Adds a Competitive Intensity to the US Branded Generics Market The share of Indian players in the US branded generics market is expected to further increase in the next five years primarily due to the following: High R&D Spend: Large Indian players continue to invest significantly in R&D. Leading Indian players have increased their R&D budgets over the last few years, indicating a good launch pipeline of these players Entry of New Indian players: The U.S. market continues to see the entry of new players every year, and these companies are expected to further drive the share of Indian players in overall ANDA approvals CDMO Entry: Few Indian CDMOs are also planning to enter the U.S. market Focus of Indian players is on specialty/complex generics where competition is relatively lower and launching products early. See also Global Pain Management Devices Market is estimated to grow at a healthy CAGR of 9% to reach USD3.5 billion by 2026 Unmet Patient Needs Across Indications Fuels the Growth of the US Branded Generics Market The unmet patient needs in cardiovascular, gastroenterology, diabetology, oncology, pain management, and dermatology therapeutic areas drives the US branded generics market. Other application areas that are also witnessing increased demand are women’s health, neurology, ophthalmology, respiratory, hormonal, anti-psychotic, and infectious diseases. Organic and Inorganic Growth Strategies Adopted by Leading Players to Establish Their Foothold in US Branded Generics Market The leading players operating in the US branded generics market have adopted both organic and inorganic growth strategies such as acquisitions, and partnerships to garner a larger market share. For instance, In November 2021, ANI Pharmaceuticals completed the acquisition of Novitium Pharma, significantly enhancing its R&D capabilities and scale of generics and CDMO businesses. Competitive Landscape Analysis: US Branded Generics Market The US branded generics market is marked by the presence of the prominent market players such as follows:- Teva, Mylan Sandoz Sun Pharma Hikma, among others See also Global Bioinformatics Market is projected to observe a CAGR of 13–14% by 2027 The forecast for the US branded generics industry appears positive due to the patent expiration of important pharmaceuticals, the rising significance of Indian businesses, higher profitability than unbranded generics, and unmet patient demands across several therapeutic categories. Get Detailed Insights on US Branded Generics Market @ https://meditechinsights.com/us-branded-generics-market/

Tag: US Branded Generics Market

The US Branded Generics Market was valued at $19.1 billion in 2022 and is expected to increase at a pace of around 9-10% by 2027.

The Global Single-use Bioreactors Market is set to surge at a high CAGR of 20% by 2029.

Global Biologics CDMO Market is set to soar at substantial CAGR of 14–16% in the next five years.

Oncology Information System Market Projected to Witness High Growth of 8% from 2024 to 2029

The Transplantation Market Expected to Grow at a 9-10% CAGR by 2029, Fueled by Advancements in Transplant Technologies

The Bioburden Testing Market Maintains Strong CAGR with Growing Demand for Sterilization Assurance

The Fluoroscopy Equipment Market is Poised to grow at a CAGR of 5–7%.

The Bionic Contact Lenses Market is poised to grow at a high CAGR of 11-13%

Global Biosimulation Market Envisions a Promising Future to Have a High 15-20% Growth by 2028

Global Intraocular Lens (IOLs) Market Expecting a Decent 5-6% CAGR in the Next 5 Years

The Cardiology Information System (CIS) Market is projected to grow at a healthy CAGR of 8-10% over the next few years.